5 of Last Week's Biggest Losers

There's never a shortage of stocks going the wrong way in any given chunk of time. No stock goes straight up, and sometimes fundamentals can get a bit wobbly. Let's take a closer look at five of this past week's biggest sinkers.

Source: Barron's.

Let's start with Rally Software Development. The ironically named sinker lost a third of its value after posting uninspiring financial results. The provider of cloud-based enterprise software solutions plunged after posting another quarterly loss and hosing down its top-line outlook for the entire fiscal year. Rally now sees a loss of as much as $1.36 a share for fiscal 2015 -- less than it had originally projected -- but its new revenue target of $87 million to $90 million is short of its earlier range of $91.5 million to $93.5 million.

It was a bad week for China's solar energy stocks. Yingli Green Energy was one of the many stocks to take a hit after the U.S. Commerce department made a preliminary decision to impose duties of as much as 35% on imports of solar energy products. This will naturally make it harder for Chinese companies to land stateside deals, but the double-digit percentage drops across several of the players may be overdone given the global inevitability of solar power. 

Zynga was a zinger after the casual gaming giant's CEO failed too woo institutional investors at an investing conference. CEO Don Mattrick -- who left a leadership position at Xbox to take the helm at Zynga -- presented at the Bank of America Merrill Lynch 2014 Global Technology Conference on Wednesday afternoon. One analyst in attendance argued that there's a lack of visibility at Zynga given the fickle nature of gamers and how they've been reacting to its more recent releases. You can arrive at your own conclusion by streaming a webcast of the presentation. 

Aeropostale continued its descent after another rough week. Nomura Securities cut its price target on Aeropostale as the once trendy apparel retailer struggles to resonate with shoppers. It has posted six consecutive quarterly losses, and the near-term outlook isn't a whole lot brighter. Nomura's price target on the troubled retailer is going from $6 to $5.

Finally we have Novavax taking a hit after completing a dilutive secondary offering. It's not a good sign when you sell $100 million worth of stock at $4 when your stock had closed at $5.08 the day before. This is the second time over the past year that the vaccine developer has turned to a secondary offering, leading to investors considering the dilution a way of life if they want to invest in the Novavax.